Across TCGA pan-cancer cohorts, OMA1 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated OMA1 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher OMA1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated OMA1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC and COAD are the cancer types where OMA1 Mutation most reproducibly stratifies survival.